FDA Approval For Lysosomal Storage Disease Screen In Newborns
Baebies, Inc., a company focused on advancing newborn screening and pediatric testing, announced today it has received de novo clearance from the U.S. Food and Drug Administration (FDA) for SEEKER. SEEKER quantitatively measures the activity of lysosomal enzymes α-L-iduronidase (IDUA), α-D-glucosidase (GAA), β-glucocerebrosidase (GBA) and α-D-galactosidase A (GLA) from newborn dried blood spot specimens. Reduced activity of these enzymes may be indicative of lysosomal storage diseases (LSDs) Mucopolysaccharidosis Type I (MPS I), Pompe, Gaucher or Fabry, respectively.
“Although these LSDs have FDA approved therapies, this is a significant milestone for the LSD community, as SEEKER is the first FDA cleared product for LSD testing,” said Vamsee Pamula, President and Co-Founder of Baebies. “FDA’s clearance of SEEKER resulted from a thorough and rigorous review. We look forward to providing SEEKER kits to implement safe, effective, easy and reliable screening for LSDs. SEEKER is the only FDA authorized test on the market.”
Newborn screening, widely recognized as one of the most successful public health programs in the U.S., ensures that all babies are screened for certain serious conditions at birth. The program started more than 50 years ago and has since expanded to include more than 30 metabolic and genetic diseases. The recent addition of Pompe disease and MPS I to the Recommended Uniform Screening Panel (RUSP) have brought more recognition to the benefit of early detection through newborn screening for LSDs.
“As LSDs are being added to the RUSP, state newborn screening programs are making plans to begin screening. FDA clearance enables state laboratories to confidently implement testing while minimizing the validation effort resulting in a cost effective implementation,” said Bradford Therrell, Jr., PhD, the Director of the National Newborn Screening and Global Resource Center.
This article has been republished from materials provided by Baebies. Note: material may have been edited for length and content. For further information, please contact the cited source.
Academic Redesigns FDA-Approved MabThera to Treat ALSNews
Researchers have redesigned a portion of the FDA-apporved MabThera for better-targeted treatment of ALS.READ MORE
Biogen's MS Drug FAMPYRA Granted Standard Marketing Authorization in EUNews
Biogen's drug FAMPYRA improves walking for MS sufferers and has been granted standard marketing authorization.READ MORE
Cost-Efficient Chemical Reaction Could Yield New Fuels and MedicationsNews
UCLA scientists have developed a novel and inexpensive chemical reaction that can cut carbon-hydrogen bonds and incorporate methane into larger molecules.READ MORE
Comments | 0 ADD COMMENT
2nd Partnership in Biocontrol, Biostimulants & Microbiome Congress
Nov 02 - Nov 03, 2017
5th Annual Outscourcing in Clinical Trials Nordics 2017
Oct 10 - Oct 11, 2017